Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin in pediatric NDO (MARMOSET)
NCT01981954Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2013
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of solifenacin in neurogenic detrusor overactivity (NDO), sponsored by Astellas Pharma. Primary endpoint: Maximum Cystometric Capacity at 24 weeks. Started Sep 2013; status: completed.
02
Drugs
solifenacin
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT01981954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01981954.